DENVER--(BUSINESS WIRE)--March 9, 2006--Myogen, Inc. (Nasdaq:MYOG) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ambrisentan, the Company's type-A selective endothelin receptor antagonist (ERA), currently in Phase 3 clinical evaluation for the treatment of patients with pulmonary arterial hypertension (PAH).
